Market research
DNTH Dianthus Therapeutics Inc.
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 141.2143
- Dividend yield
- Not available
- Beta
- 0.06
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US2528281080
- Market cap
- 6B
- P/E ratio
- Not available
- Analyst target
- 141.2143
- Dividend yield
- Not available
- Beta
- 0.06
About
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the DNTH discussion.
No comments yet
Start a focused discussion about DNTH.